Overview
Aligo Alfa Spółka Z Ograniczoną Odpowiedzialnością is a venture capital firm that invests in early-stage startups focused on HealthTech and CleanTech innovations. The company supports projects such as dietary supplements for dermatological issues, digital therapeutics for cancer patients, and SaaS platforms for carbon footprint management. Additionally, it provides consulting services to help companies secure funding and accelerate growth.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Announcement to creditors about the reduction of share capital
Wellbeing Polska joins Mavie Work – Aligo Venture Capital exit
LUX MED acquires Mental Path Group
Feyenally in the prestigious Techstars Healthcare Accelerator program powered by Permanente Medicine
Prosoma raises 4.4 million euros in pre-Series A funding
Smarter Diagnostics with ESA contract as part of the Ax-4 mission
Bank accounts
Registered as a VAT taxpayer on 2018-09-18. Active
97 1600 1462 1085 5099 5000 0002- 28 1750 1325 0000 0000 3998 7147
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
General partners
Manner of representation
The company is represented and its affairs are conducted by the general partner.
Beneficial owners
| Person | Rights |
|---|---|
Tomasz Tadeusz Chwiałkowski (47)  | Other natural person. |
Joanna Elżbieta Grabowska (49) | Osoba kontrolująca wspólnika jedynego komplementariusza oraz wspólnik posiadający 99,78% w spółce komplementariusza spółki będącej akcjonariuszem posiadającym 87,54% akcji w spółce zgłaszanej. |
Tomasz Grabowski (53) | Osoba kontrolująca wspólnika jedynego komandytariusza oraz prezes zarządu w spółce komplementariusza spółki będącej akcjonariuszem posiadającym 87,54% akcji w spółce zgłaszanej oraz wspólnik posiadający 49,75% udziałów w komplementariuszu spółki zgłaszanej i prezes zarządu spółki posiadającej pozostałe 49,75% udziałów w komplementariuszu spółki zgłaszanej. |
Łukasz Mańkowski (38) | Other natural person. |
Subsidiaries
| Name | Share value | Stake | |
|---|---|---|---|
Unicorn Vr Worldsp. z o.o. | 553.75 USD | 20% | |
Britescopesp. z o.o. | 9,940.57 USD | 14.3191% | |
Biominds Healthcaresp. z o.o. | 1,485.68 USD | 23.2558% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Alfa Pro CapitalS.K.A. | $1,277,753.39 | alfaprocapital.pl | |
| TAR Heel Capital Pathfinder VcS.K.A. | $932,915.29 | thcpathfinder.vc | |
| Satus StarterS.K.A. | $706,559.40 | satus.vc | |
| EEC MagentaS.K.A. | $657,160.49 | eecventures.com | |
| Blue Investments Asisp. z o.o. | $528,234.40 | blue-investments.pl | |
| Credit Omegasp. z o.o. | $452,391.10 | alphacredit.pl | |
| ABS InvestmentS.A. | $440,355.87 | absinvestment.pl | |
| Cofounderzone Corporate Angel Fund AsiS.K.A. | $411,614.83 | cofounder.zone | |
| KvarkoS.A. | $357,171.07 | kvarko.pl | |
| ASI Rds Fundsp. z o.o. + limited partnership | $337,460.74 | rdsfund.com |
Change history
| Date | Event |
|---|---|
| 2026-09-22 | PKD change (Removed: 64.30.Z; Added: 64.31.Z) |
| 2023-01-16 | Share capital change (7,000,000.00 PLN → 8,050,000.00 PLN) |
| 2022-01-05 | Share capital change (5,000,000.00 PLN → 7,000,000.00 PLN) |
| 2021-08-26 | Share capital change (4,000,000.00 PLN → 5,000,000.00 PLN) |
| 2020-12-30 | Share capital change (3,000,000.00 PLN → 4,000,000.00 PLN) |
FAQ
Last updated: 2026-09-22